COMMUNIQUÉS West-GlobeNewswire

NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
22/12/2025
Ghent, Belgium, Dec. 22, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, [...]
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
22/12/2025
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY [...]
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040
22/12/2025
COMMUNIQUE DE PRESSE LE BREVET POUR LE MASITINIB DANS LE TRAITEMENT DE LA DRÉPANOCYOSE A ÉTÉ OFFICIELLEMENT ACCORDÉ AUX ÉTATS-UNIS AVEC UNE PROTECTION JUSQU'EN 2040 CETTE DÉCISION RENFORCE LE PORTEFEUILLE DE PROPRIÉTÉ [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2025
22/12/2025
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
22/12/2025
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-treated participants regained previously [...]
PracticeLink Supports the Next Generation of Clinicians with Fall 2025 First Practice Fund Scholarships
22/12/2025
ST. LOUIS and HINTON, West Virginia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the leading online physician job board, announced today the [...]
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
22/12/2025
- Halneuron ® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically [...]
ALK – Financial calendar for the 2026 financial year
22/12/2025
2026 financial calendar for ALK ( ALKB:DC / OMX: ALK B ): 23 January 2026: Silent period 20 February 2026: Annual report 2025 16 March 2026 at 4.00 p.m.: Annual General Meeting Written requests to have specific business [...]
Wholeview Wellness Joins the Lumina Therapy Alliance, Expanding Access to In-Person Addiction-Focused Psychotherapy for Employees and Their Families
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , the nation’s leading collective of highly vetted, in-person mental health practices, is proud to announce that Wholeview Wellness , the boutique, out [...]
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
22/12/2025
Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive [...]
PeopleOne Health Selected by Orlando Regional REALTOR® Association to Deliver First-of-Its-Kind Healthcare Solution for Realtors
22/12/2025
Partnership to expand access to personalized primary care, including same-day appointments and mental health services, for more than 18,000 Central Florida real estate professionals ORLANDO, Fla., Dec. 22, 2025 (GLOBE [...]
Omada Health to Participate in J.P. Morgan Healthcare Conference
22/12/2025
SAN FRANCISCO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 44th Annual J.P. [...]
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting 2025
22/12/2025
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World [...]
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
22/12/2025
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- [...]
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
22/12/2025
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, [...]
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
22/12/2025
Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2 BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next- [...]
Vivos Inc Summarzes Preogress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported an 800% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
22/12/2025
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned [...]

Pages